Healthy sleep is associated with better cognitive performance and larger brain volume in people living with diabetes, heart disease, or stroke — and the relationship appears stronger in this group than in people without cardiometabolic disease, according to a large analysis of UK Biobank data led by researchers at Karolinska Institutet.
The study, published online November 4, 2026, in the Journal of the American Heart Association (DOI: 10.1161/JAHA.126.051940), drew on data from 408,977 middle-aged and older UK Biobank participants, including 54,017 who had at least one cardiometabolic condition — type 2 diabetes, coronary heart disease, or stroke. A subset of 34,913 participants also had brain MRI scans available, allowing the researchers to connect sleep health directly to measurable brain structure rather than relying on cognitive testing alone.
What the Data Showed
Participants with cardiometabolic disease who reported healthier sleep — a composite measure covering factors such as sleep duration, insomnia symptoms, snoring, and daytime sleepiness — performed modestly better than their poor-sleeping counterparts on tests of general cognition, problem-solving, and processing speed. On brain imaging, healthier sleepers in this group also had larger total brain volume and greater volumes of both grey and white matter.
The detail the researchers highlighted most was the size of the effect by subgroup: the association between sleep health and brain outcomes was more pronounced among people with type 2 diabetes, heart disease, or stroke than among participants without those conditions. In other words, good sleep didn't just correlate with a healthier brain across the board — it appeared to matter more for the people whose brains are already under the greatest biological strain from chronic disease.
Why This Fits a Larger Pattern
Cardiometabolic disease is already a well-established risk factor for cognitive decline and dementia, driven by mechanisms that include vascular damage, chronic inflammation, and disrupted glucose metabolism — all of which can also degrade sleep quality, creating a plausible two-way relationship rather than a clean cause-and-effect story. The Karolinska team is careful to frame their findings as observational: because poor health can disrupt sleep just as easily as poor sleep can worsen health, the study cannot establish that improving sleep directly protects the brain in people with these conditions, only that the two are closely linked in a dataset large enough to detect reliable subgroup differences.
Still, the scale of the sample — among the largest cohorts to link sleep health, cognition, and quantitative brain MRI findings in the same analysis — gives the subgroup comparison more weight than a smaller study could. Prior UK Biobank work has separately tied irregular sleep-wake patterns and inconsistent bedtimes to cardiovascular risk and brain shrinkage, and this analysis extends that line of research by showing the sleep-brain relationship isn't uniform across the population; it concentrates in exactly the patients who have the least biological margin to lose.
What This Means for Patients
For the millions of people managing type 2 diabetes, heart disease, or a history of stroke, this study adds sleep health to a list of modifiable factors — alongside diet, exercise, and medication adherence — that may influence long-term cognitive outcomes. Unlike many risk factors tied to cardiometabolic disease, sleep habits are often within a patient's control and don't require new medication: treating underlying insomnia, addressing snoring or suspected sleep apnea, and protecting consistent sleep duration are interventions most primary care teams can already act on. The Karolinska researchers frame healthy sleep as an "accessible and achievable" target precisely because, unlike reversing existing vascular damage, it's a lever patients and clinicians can start pulling immediately — even as larger, longer-term studies work out exactly how much of the brain benefit is sleep's doing.